Unicycive Therapeutics Announces Resignation of Director Gaurav Aggarwal

On April 6, 2026, Unicycive Therapeutics, Inc. announced the resignation of Gaurav Aggarwal from its Board of Directors, effective immediately. According to the filing, Dr. Aggarwal's departure was not due to any disagreements with the Company, its management, or the Board regarding operations, policies, or practices. The Company expressed its appreciation for his service on the Board. No successor was named in the filing, and the resignation appears to be a routine change in board composition. Unicycive Therapeutics is a clinical-stage biotechnology company focused on developing therapies for kidney diseases, though this specific filing pertains strictly to corporate governance and director changes.